Transcript Highlights:

• Item number two is the December 2025 pharmacy formulary recommendations.
• Next item up is the January 2026 pharmacy formulary recommendations.
• Next item up is the January 2026 pharmacy formulary recommendations.
• Moving to the February 2026 pharmacy formulary recommendations.
• more than we're paying our independent pharmacies within the plan?

Summary: The State Insurance Programs Oversight Subcommittee met to review and approve several Employee Benefits Division (EBD) and pharmacy formulary actions. Grant Wallace, director of EBD and the Office of Property Risk, presented a $280,000 Boston Consulting Group contract to help develop the third-party administration RFP, and the committee approved it. The committee also approved the December 2025, January 2026, and February 2026 pharmacy formulary recommendations, along with February 2026 medical drug recommendations. The formulary changes focused on removing prior authorization for injectable migraine CGRPs, replacing a discontinued capsule with a tablet, updating items for FDA guidance, and leaving some drugs not covered when lower-cost alternatives or insufficient efficacy data existed. For February 2026, EBD recommended removing Skyrizi and Renvoke in favor of lower-cost biosimilars and other alternatives, re-tiering several drugs to encourage generics, adding an anti-seizure medication developed by the Department of Defense, and adding a subcutaneous version of Keytruda for faster administration. The medical drug list similarly shifted toward biosimilars and aligned coverage for Skyrizi and Renvoke across pharmacy and medical settings. Members raised broader questions about the impact of new pharmaceutical discount programs such as Trump RX and Mark Cuban Cost Plus, as well as concerns about PBM compliance and whether Navitus might be violating state law or paying affiliate pharmacies more than independent pharmacies. Wallace said the new programs and their effects were still being studied, that EBD was working with Navitus to evaluate pricing opportunities, and that Navitus had said it was in compliance with Rule 118, though additional research and auditing were underway. All items were approved by voice vote, and the meeting adjourned after no further business.

Transcript Highlights:

• As Chair Beerman pointed out, we did some phenomenal work with hospitals and pharmacy this year.
• Chair Berman replied that the directed pharmacy payment will not need federal approval.
• It will limit the pharmacies to non-PBM-owned pharmacies.
• , directed pharmacy dispensing payment, how<00:14:14.240><c> that</c><00:14:14.480><c> works,</c><00:
• It will limit the pharmacies to non-PBM-owned pharmacies.

Bills: HF2436, HF2435

Keywords: child welfare, economic assistance, child care, grant program, video security cameras, healthcare, dementia services, public health funding, opioid prevention, women's health, community health boards, mental health, 1183, house

Transcript Highlights:

• We're also looking at pharmacy benefit managers, so PBM, pharmacy benefit managers, cost controls, and
• Five states have a pharmacy carve-out for managed care.
• It basically took out a lot of our pharmacies, our mom-and-pop pharmacies.
• And one of the pharmacies that also closed off was Rupi's Drug.
• You talked about pharmacies. Tell us about how it affected patients.

Transcript Highlights:

• </c><00:40:09.960><c> my</c> insulin to our contract pharmacies my insulin to our contract pharmacies
• </c> ship it there we have only one Pharmacy ship it there we have only one Pharmacy on<00:40:35.640>
• </c> managed list of practicing pharmacy managed list of practicing pharmacy technicians<00:50:32.119
• </c><00:51:55.960><c> um</c> so I could get home to my Pharmacy um so I could get home to my Pharmacy
• </c> licensed pharmacists our pharmacy licensed pharmacists our pharmacy technicians<00:52:51.760><c>

Keywords: 910, house, all

Summary: The joint hearing covered HB 553 on biomarker testing coverage, HB 556 on colorectal cancer screening access, and later HB 712 on 340B drug pricing. For HB 553, the American Cancer Society Cancer Action Network, patient advocates Natalie Heyman and Susan Hirano, a surgical oncologist, and the American Lung Association strongly supported the bill, arguing that biomarker testing should be covered when ordered by a doctor and guided by current evidence. DHS and several insurers offered comments and requested amendments, with DHS saying it appreciated the intent but wanted changes. The committees then voted to pass HB 553 with amendments, including a House draft and a defective date of July 1, 3000; both the House Health and Human Services and Homelessness committees adopted the recommendation unanimously. For HB 556, testimony focused on closing gaps in colorectal cancer screening, especially for uninsured and underinsured patients who can get stool-based screening but then cannot access follow-up colonoscopies. Community Clinic of Maui, ACS CAN, and the American Cancer Society supported the bill, with ACS CAN urging a program similar to the breast and cervical cancer control program and offering amendments. DHS requested that the program and appropriation not conflict with executive budget priorities, and the committees noted technical amendments, a defective date, a blank appropriation amount, and corrections changing Medicare references to Medicaid. HB 556 was also passed with amendments by both committees. The hearing then moved to HB 712 on 340B drug pricing and contract pharmacies. The Department of Health and the Attorney General’s office expressed concern that the bill would require the state to regulate private commercial activity and said the department lacked the expertise and resources to implement it as written, suggesting it might belong in a different statutory section. In contrast, PhRMA opposed the bill, while Hawaii Pacific Health and Hawaii Island Community Health Center supported it, saying 340B savings are important for hospital services and patient access to low-cost medications, especially where manufacturers have restricted shipments to contract pharmacies. No vote on HB 712 was taken in the portion provided.

Transcript Highlights:

• Leveraging the accessibility of pharmacies and the broad pharmacy network across our rural state, these
• Leveraging the accessibility of pharmacies and the broad pharmacy network across our rural state, these
• It's the pharmacy benefit managers by controlling the money.
• can't have... ...pharmacy now and I said, I lost my insurance.
• The system, as it currently is, is pharmacy benefit managers decide.

Keywords: 908, all

Summary: The committee first took up Senate Bill 2401, which would require physicians to complete continuing education on nutrition and metabolic health as part of the state’s rural health transformation effort. HHS supported the bill, saying it would help physicians better address chronic disease and preserve federal grant points tied to the state’s application. A member of the public also testified in favor, arguing that better nutrition education could improve diabetes outcomes and reduce costs. The committee then adopted an amendment to add the Board of Occupational Therapy Practice to the background-check statute so the occupational therapy compact could proceed, and it passed the bill as amended on a roll call vote. The committee next heard House Bill 1621, which would require the Presidential Fitness Physical Fitness Test in elementary, middle, and high school physical education courses. HHS said the bill was part of the rural health transformation application and could help preserve federal funding, but members raised many questions about the test’s criteria, adaptive options for students with disabilities, equipment needs, and whether the bill should apply to non-public schools. Senator Clemens offered an amendment to limit the requirement to public schools, but it failed. Senator Hogan then offered an amendment to clarify exemptions and allow DPI to align implementation with federal guidance; that amendment passed. A further amendment adding language allowing DPI to establish criteria for and exceptions to the test also passed. The committee then approved the bill as amended on a roll call vote. The committee also considered House Bill 1622, which joins North Dakota to the physician assistant licensure compact. HHS said the compact would improve access to care, especially in rural areas, support military families, and help preserve rural health transformation funding. Members noted the compact had been discussed in a prior session and that many earlier concerns had been resolved. After brief discussion about the compact process and its consistency with other interstate compacts, the committee voted to do pass the bill. Finally, the committee began Senate Bill 2402, which expands pharmacists’ prescriptive authority and therapeutic substitution powers. HHS and the Board of Pharmacy supported the bill as a way to improve access to care and maintain rural health transformation funding. Senator Roers introduced a detailed amendment negotiated with the Board of Medicine and Board of Pharmacy to narrow and clarify the bill, including notification requirements, limits on certain drug categories, and patient-protection language for therapeutic substitution. The Board of Pharmacy then testified in support of the broader bill and explained the CLIA-waived testing provisions and the repeal of the older, narrower pharmacist-testing language. The hearing and amendment discussion were still underway when the transcript ended.

Transcript Highlights:

• </c> costs that are not a contract pharmacy costs that are not a contract pharmacy so<00:57:49.839><c
• , more than one contract pharmacy.
• </c> more than one contract pharmacy. more than one contract pharmacy.
• While it was not heard in pharmacy.
• from the pharmacy.

Keywords: 919, house, all

Summary: The committee first approved the March 11, 2026 minutes, then heard House File 4048, which would exempt chiropractors from Minnesota’s provider tax if they are no longer eligible to provide chiropractic benefits under Medicaid/MinnesotaCare. Representative Robbins said the bill corrects an unfair situation because chiropractors still pay the tax even though the benefit was eliminated. Testifiers from the Minnesota Chiropractic Association and a longtime chiropractor supported the bill, arguing that most chiropractors are small-business owners and should not pay a tax for services they can no longer provide. Several members said they supported restoring chiropractic coverage instead of changing the tax, and there was discussion about whether the tax applies to all providers and whether it is effectively passed on to patients. The committee adopted a motion to recommend HF 4048 to the Committee on Taxes. The committee then took up House File 3893, as amended, a bill to restrict artificial intelligence from engaging in psychotherapy or counseling with humans. The author and supporters said the bill is intended to prevent AI chatbots from posing as therapists or counseling vulnerable people, citing reports of suicides and other harms linked to chatbot interactions. The A2 amendment was adopted; the author said it reflected stakeholder concerns and added informed-consent language. Testifiers in support, including a psychologist and a suicide-prevention nonprofit leader, urged strong safeguards and said AI should not replace licensed professionals in crisis settings. Other testimony raised concerns about overbreadth and unintended effects. TechNet and a rural mental health provider said the bill should be narrowed so it applies to clinical therapy rather than wellness or educational tools, and should allow supervised AI uses such as transcription and administrative support. Members discussed rural access, existing licensing-board authority, privacy laws, and whether the bill should target AI companies directly rather than licensed clinicians. The transcript ends during continued discussion of HF 3893, with no final committee action shown in the excerpt.

Transcript Highlights:

• I'm the pharmacy director at DHS.
• We don't work for pharmacy plans.
• We often work with local pharmacies, especially independent pharmacies, to help them with their patients
• Um, but the reason operating pharmacy.
• So, they saw a by pharmacy students.

Keywords: 1183, house

Keywords: 1191, senate, all

Transcript Highlights:

• benefit, because that would fall under your pharmacy benefit.
• managed care plans for the reduction of pharmacy reimbursements; to provide for pharmacy benefit manager
• It provides additional reimbursement guidelines for pharmacy benefit managers.
• Real communities are hit the hardest when those pharmacies are forced to close their doors.
• Don Caffrey here on behalf of the Independent Pharmacies Association.

Keywords: 965, house, all

Transcript Highlights:

• , the same; the drug manufacturers, the same; the pharmacy benefit managers, the same; and the Pharmacy
• I know originally it was under the Board of Pharmacy, which I don't think anybody was happy with, and
• I'm Brendan Joyce with Medicaid, the pharmacy director.
• We are not the pharmacy experts, but we will certainly implement to the best of our ability if given
• I think if the intent is to look at the carriers, the PBMs, drug manufacturers, pharmacies, etc., we'd

Keywords: 908, all

Summary: The subcommittee met on SB 2370 with a quorum present and focused on how to handle proposed 340B-related reporting language. Members discussed three main paths: adopt the LC draft with reporting requirements for covered entities, PBMs, insurers, and manufacturers; convert only the PBM/insurer/manufacturer portions into a study; or turn the entire proposal into a study. Representative Dobervich explained that the study version would keep the same subject areas but delay initial reporting so the data could be analyzed more thoughtfully, and she noted gaps in the original amendments, including federally qualified health centers participating in 340B, 340B contract pharmacies, and a clearer plan for data analysis and administration. Testimony from HHS and the Insurance Department emphasized that collecting data is different from analyzing it and that any version would need clear authority, confidentiality protections, and a designated agency willing to collect, analyze, and publish the information. The Insurance Department said it could potentially collect data but would likely need additional budget resources for analysis, and it noted that the pending PBM bill, SB 1584, could affect what information is already available through regulation. A representative of the North Dakota Pharmacists Association said SB 1584 contains some reporting but is not as comprehensive as the proposal under discussion. Members also discussed whether the proposal belonged in an insulin bill at all, with concerns raised about germaneness and the possibility of sending the matter to the Delayed Bills Committee or placing study language elsewhere. No vote was taken. The subcommittee adjourned after members agreed to continue refining the language over the weekend and bring options back to the full committee, with several members expressing a preference for a combined version that includes both reporting and study elements.

Transcript Highlights:

• James Kuski, Board of Pharmacy, and support.
• only get it at my one little pharmacy.
• only get it at my one little pharmacy.
• talking about are available at every pharmacy.
• talking about are available at every pharmacy.

Keywords: 912, senate, all

Summary: The joint Health, Human Services, and Labor and Technology committee heard testimony on SB 447, a Department of Health pilot program related to recruitment, and SB 1043, a tax measure. On SB 447, the Department of Health said the pilot had streamlined hiring by delaying minimum-qualification review until later in the process, while the Department of Human Resources Development objected that parts of the bill could conflict with civil service rules, due process rights, and equal pay requirements. Several labor and employee groups testified, with some supporting the pilot as a way to address vacancies and others warning about merit-system concerns. The committee later voted to pass SB 447 as is. On SB 1043, testimony was mixed but largely focused on the bill’s tax changes, especially the proposed increase to the general excise tax and exemptions or credits for lower-income households. Supporters, including labor groups and housing/worker advocates, argued the bill would reduce burdens on working families, help with food insecurity, and keep residents in Hawaiʻi. Opponents, including the Tax Foundation of Hawaiʻi and some community witnesses, said the general excise tax is regressive and would raise costs across the state. The committee voted to advance SB 1043 with substantial amendments, deleting most of the bill except section two and setting a far-future effective date, while noting the fiscal impact had not been provided. The committee also deferred SB 633 and later deferred SB 1633 for further decision-making, scheduling continued consideration for February 12, 2025, in Room 225. The hearing included standard instructions on one-minute testimony, written testimony, and Zoom procedures, and the committee adjourned after taking the above actions.

Transcript Highlights:

• ability to transfer controlled prescriptions, specifically medications such as Vyvanse, from one pharmacy
• Right now, when one pharmacy is out of stock, we're often forced into a frustrating loop: back to the
• doctor for a brand-new prescription, then off to another pharmacy, hoping they'll have it.
• Allowing prescriptions to be transferred between pharmacies solves this. It reduces stress.
• Providers can be hard to reach after hours or on weekends, and pharmacies often cannot refill without

Keywords: 995, all

Summary: The Joint Committee on Financial Services held a hearing with Chair Jamie Murphy and Senate co-chair Senator Feeney presiding. Members asked witnesses to keep testimony to three minutes and noted that written testimony could still be submitted. The committee heard testimony on several health insurance and pharmacy-related bills, including a proposal to allow controlled prescriptions to be transferred between pharmacies within the same chain, legislation affecting health savings account (HSA)-compatible plans and future insurance mandates, a bill on small business health insurance incentives, and H. 1212 on emergency insulin access. Several parents and patients testified in support of emergency insulin access, describing severe diabetes emergencies, diabetic ketoacidosis, prescription delays, and the need for pharmacists to dispense insulin in urgent situations when doctors or insurers are unavailable. A parent also described the burden of repeatedly obtaining new prescriptions for ADHD medication when pharmacies are out of stock. Witnesses supporting the HSA bill argued that state coverage mandates can unintentionally disqualify HSA-qualified plans and that the bill would preserve tax advantages for enrollees while avoiding repeated legislative fixes. A representative of the Retailers Association supported the small business health insurance incentives bill, saying it could help retain small employers in the merged market by allowing carriers to offer financial incentives tied to cooperative purchasing and utilization efforts. One witness, Kathleen Demarest, testified against a co-pay assistance restriction, saying a state rule had unexpectedly cut off her drug assistance before a generic was actually available, leaving her with very high out-of-pocket costs. Committee members asked a few clarifying questions about HSAs, insulin dispensing, and school support for diabetes care. After all scheduled witnesses had testified and no additional testimony was offered, the committee voted to close the hearing.

Transcript Highlights:

• First up, we have Alana Isobe, DCCA PVL, Board of Pharmacy, providing comments.
• ,</c><00:08:59.200><c> providing</c> DCCAP PVL, Board of Pharmacy, providing DCCAP PVL, Board of Pharmacy
• Um, my name is Christopher Fernandez, executive officer for the Board of Pharmacy.
• </c><00:10:14.000><c> We're</c> officer for the board of pharmacy.
• We're officer for the board of pharmacy.

Keywords: 912, senate, all

Summary: The HHS committee met in Room 224 and announced the hearing was being streamed live, with a one-minute limit on testimony. The chair explained that written testimony had already been reviewed and that speakers should either add new comments or stand on their written testimony. The committee first heard SB 2211, an emergency appropriation to the Department of Human Services. Testimony was overwhelmingly in support, including DHS, Aloha United Way, the Hawaii Food Industry Association, the Hawaii Public Health Institute, Catholic Charities, and many individuals. Supporters emphasized the importance of maintaining SNAP-related food assistance and emergency food delivery, while Catholic Charities raised a question about whether the bill’s language would also reach food banks serving food-insecure households that are not on SNAP. No opposition was heard and the bill was moved on without questions from members. The committee then heard SB 2025, which would exempt actively practicing advanced practice registered nurses from jury duty. Testimony was broadly supportive from nursing and health organizations, including the Hawaii American Nurses Association, the Hawaii affiliate of the College of Nurse Midwives, the Hawaii State Board of Nursing, and others. One witness from Kaiser Permanente requested an amendment to include physician assistants, and a committee member asked the Board of Nursing to review that request. The bill otherwise drew no opposition and no further member questions. SB 2038, relating to medication labeling, drew the most extended discussion. The measure would change labeling requirements for certain abortion medications, and testimony was split between supporters who framed it as a privacy and access issue and opponents who raised patient safety, ethics, and transparency concerns. The Department of Health supported the intent but requested an amendment to allow quicker access to private information during investigations without a subpoena. The Board of Pharmacy said it supported the written comments but noted operational challenges and possible cost impacts, while Kaiser said compliance would likely require manual workarounds and could slow pharmacy processes. The chair and members questioned whether patients could simply remove labels themselves, but witnesses said there could still be safety and access issues if the patient is not the one receiving the prescription. The committee then moved on to SB 2050, relating to chiropractic, which received support from the Hawaii Board of Chiropractic and the Hawaii State Chiropractic Association, with no substantive opposition noted. The hearing later turned to SB 201, relating to insurance, which appeared to be a new mandated-benefit measure tied to infertility/IVF coverage. The Hawaii Civil Rights Commission provided comments, while Hawaii Family Forum opposed the bill, arguing it went beyond medical infertility and raised ethical and public policy concerns. Kaiser and the Hawaii Association of Health Plans both asked for a study or audit, saying the measure could create new insurance mandates and increase costs for residents and employers. Private Work Hawaii strongly supported the bill as an equity issue. The committee noted there was no quorum for decision-making and deferred action on the measure to a later hearing, then recessed.

Transcript Highlights:

• This instrument provides relative to pharmacy benefit managers to provide for definitions.
• Thus streamlining the process for pharmacy appeals.
• It prohibits using a formulary to ban the use of certain pharmacies by an enrollee.
• It prohibits using formulary to ban the use of certain pharmacies by an enrollee.
• Pharmacies can't predict reimbursement. It masks underpayment and makes auditing difficult.

Keywords: 965, house, all

Transcript Highlights:

• </c> pharmacy.
• In many cases, pharmacy pharmacy.
• </c><04:48:58.480><c> The</c><04:48:58.718><c> pharmacy</c> than the pharmacy rebates.
• The pharmacy than the pharmacy rebates.
• </c> pharmacy from containing a gag clause. pharmacy from containing a gag clause.

Keywords: 1189, house, all

Transcript Highlights:

• </c><00:16:48.800><c> and</c> talking about the spend to pharmacy and talking about the spend to pharmacy
• I'm owner of Columbia Pharmacy in Columbia.
• I've got a short Pharmacy in Colombia.
• An independent pharmacy must than $4.
• ><c> access</c><01:13:39.360><c> across</c> helps preserve pharmacy access across helps preserve pharmacy

Keywords: 958, all

Summary: The Medicaid Oversight and Advisory Board met on February 23, 2026, approved the January 12 minutes, and then focused primarily on Kentucky Medicaid’s coverage and potential expansion of GLP-1 drugs, especially for weight loss. Department for Medicaid Services Commissioner Lisa Lee explained that Medicaid currently does not cover drugs for weight loss, anorexia, or weight gain, but the department had filed a regulation to remove that blanket exclusion so GLP-1s could be covered when used for an underlying health condition. She said the administrative regulation review subcommittee found the regulation deficient, and the co-chairs wanted the board to discuss the policy and financing implications before any change. DMS also said it would be open to adding caveats to ensure coverage would not extend to cosmetic weight loss alone. The department provided several data points on current utilization and spending. In 2025, Kentucky Medicaid paid for appetite-stimulating drugs such as Megestrol, Dronabinol, and Marinol, but did not pay for weight-loss drugs. For GLP-1s, DMS said coverage began in 2025 and is limited to FDA-approved medical conditions, with prior authorization requiring a type 2 diabetes diagnosis code and A1C documentation. DMS reported $234.6 million in GLP-1 spending in 2025 before rebates, about 240,931 prescriptions, and said GLP-1s accounted for 7.3% of pharmacy spend in 2024 and 8.3% in 2025. It also said there were 24,844 expansion members and 13,638 non-expansion members using GLP-1s, with spending of about $156 million and $78.5 million respectively, and that 10 pediatric weight-loss prescriptions were covered under EPSDT. The department said outcome analyses, including whether GLP-1 use reduces insulin or other diabetes treatment, are underway and should be completed in a couple of months. Members asked about cost, rebates, and whether the state should wait for more outcomes data before expanding coverage. DMS said average reimbursement to pharmacies was $975 per prescription and the average dispensing fee was $109; it also said 2025 rebate invoices totaled $90.8 million, with $7.6 million collected so far. Several members expressed concern about the high cost and the need to evaluate whether the drugs improve health outcomes before expanding access, while others noted the potential benefits for obesity and diabetes treatment. Some members also discussed whether GLP-1s are effectively being used for weight loss in diabetic patients and whether broader data collection should be used to assess long-term value. After the Medicaid discussion, Eli Lilly executive Tracy Sims presented on obesity as a chronic disease and the economic burden it creates in Kentucky. She said Kentucky’s adult obesity rate is a little over 37%, that obesity is linked to about 200 diseases, and that untreated obesity costs the state billions in GDP and hundreds of millions in state budget impact. She highlighted recent federal access programs for GLP-1s, including a Medicaid-related program that she said could lower the state share of a Zepbound prescription to about $71 per month after federal matching. No votes were taken on the GLP-1 policy question during the meeting, and the main action was the receipt of testimony and discussion of the department’s proposed regulatory change.

Transcript Highlights:

• Item number two is the December 2025 pharmacy formulary recommendations.
• Next item up is the January 2026 pharmacy formulary recommendations.
• Next item up is the January 2026 pharmacy formulary recommendations.
• Moving to the February 2026 pharmacy formulary recommendations.
• more than we're paying our independent pharmacies within the plan?

Summary: The State Insurance Programs Oversight Subcommittee met to review and approve several State Board of Finance actions related to employee benefits and pharmacy coverage. Grant Wallace, Director of the Employee Benefits Division and Office of Property Risk, presented a $280,000 Boston Consulting Group contract to help develop a third-party administration RFP, and the committee approved it. The committee then considered pharmacy formulary recommendations for December 2025, January 2026, and February 2026, along with February 2026 medical drug recommendations. Across the formulary items, Wallace explained that some drugs were being removed from prior authorization requirements, some were being updated to reflect FDA guidance or dosage changes, and others were being left not covered because lower-cost alternatives already exist or clinical evidence was insufficient. Notable changes included removing Skyrizi and Renvoke from the pharmacy formulary in favor of lower-cost biosimilars, adding certain generics, and adding a subcutaneous version of Keytruda for faster administration. The committee approved each set of recommendations by motion and voice vote. Members also raised broader questions about the impact of new drug-pricing programs such as Trump RX, Cost Plus, and other manufacturer discount efforts, as well as concerns about PBM oversight and whether Navitus is complying with state law. Wallace said the department is still studying those issues and working with Navitus to assess pricing opportunities and compliance. Senator Boyd also asked about whether affiliated pharmacies are being paid more than independent pharmacies, noting he had not received a prior response; Wallace was asked to follow up. The meeting concluded with no further business and adjournment.

Transcript Highlights:

• These pharmacies are required to submit the access to care plans annually by February. 28, the Board
• of Pharmacy is required to collaborate with the boards of Medicine and Osteopathic Medicine regarding
• certification course content the or a pharmacy implemented the provisions of this bill in September
• Pharmacy and BioLogics Solutions.
• They estimate the proof to the Board of Pharmacy of their written collaborative practice agreement.

Transcript Highlights:

• It's an analysis of pharmacy and medical claims from 2017 to 2023 for individuals living with serious
• And Barney Bishop, Small Business Pharmacies, is waving in support. Is there debate?
• And this is Senate Bill 294, dealing with collaborative pharmacy practice.
• Barney Bishop, Small Business Pharmacies, is in support. And Dr.
• The collaborative pharmacy practice agreement, also known as the CPPA, was passed into law in 2020.

Summary: The Senate Committee on Health Policy met with a quorum and heard five bills. SB 126, on prescription hearing aids, would remove Florida’s prohibition on mailing hearing aids when required tele-audiology testing and procedures are completed before sale. The sponsor said the bill would improve access, especially for people with travel or geographic barriers. The Florida Academy of Audiologists expressed support in concept but said it was still working with the sponsor on an amendment for consumer safety. The committee voted the bill favorably. SB 152 would require hospitals and ambulatory surgical centers to adopt policies using smoke evacuation systems during certain surgical procedures. Supporters, including the Florida Nurses Association and several nurses, described surgical smoke as a workplace and patient safety hazard containing harmful chemicals, viruses, bacteria, and other contaminants, and said evacuation technology is available and already required in some settings. The committee voted the bill favorably. SB 264 would expand step-therapy exemptions for severe mental illness, including certain postpartum and pregnancy-related mental health conditions, so physicians would not have to require patients to fail preferred drugs in specified circumstances. Support came from Otsuka Pharmaceuticals, NAMI Florida, and several medical and pharmacy groups, who argued that delays in effective treatment can worsen crises and increase hospital and crisis-care costs. The committee voted the bill favorably. SB 342 would create a public-records exemption for current and former AHCA employees and certain family information, citing threats and harassment directed at inspectors and regulators. President Gaetz said he generally opposes such exemptions but supported this one because the employees are not elected officials and face real safety risks. The committee voted the bill favorably. SB 294 would limit the Board of Pharmacy’s ability to add heart failure, coronary heart disease, and cardiac rhythm disorders to the list of chronic conditions eligible for collaborative pharmacy practice, keeping those conditions under direct physician management. The Florida Society of Thoracic and Cardiovascular Surgeons, Florida Medical Association, and the Florida chapter of the American College of Cardiology supported the bill, while the Florida Society of Health System Pharmacists opposed it. The committee voted the bill favorably. Senator Trumbull asked to be recorded in support of SB 126 and SB 152, and the meeting adjourned without further business.

Transcript Highlights:

• real property that would prevent or restrict the use of the real property for a grocery store or pharmacy
• Real property that would prevent or restrict the use of the real property for a grocery store or pharmacy
• real property for a grocery store... for negative use restrictions related to a grocery store or pharmacy
• owner discontinues operations on the property for the purpose of relocating the grocery store or pharmacy
• The relocated store or pharmacy is similar in size or larger and similar in scope of products sold.

Bills: HB2229, HB2274, HB2294, HB1269, HB1078

Keywords: professional engineers, registration act, licensing, engineering practice, state regulations, email regulation, commercial communications, consumer protection, data privacy, electronic mail, consumer access, real property, food security, medicine access, restriction, pawnbroker, fees, interest rates, financial regulation, pet insurance